iTeos jumps after Roche inadvertently publishes positive TIGIT data

Shares of iTeos Therapeutics (ITOS) have jumped $4.82, or 41%, to $16.57 in early trading after Roche (RHHBY) on Tuesday night inadvertently disclosed positive results from a closely watched lung cancer drug study. The second interim look at Roche’s SKYSCRAPER-01 trial leaked last night and the combo of TIGIT tiragolumab and PD-L1 Tecentriq vs Tecentriq alone in NSCLC appeared to be trending towards a survival benefit and the data looked “good,” which is likely to renew TIGIT interest, BofA has told investors.